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Objectives This study sought to compare clinical outcomes and angiographic ﬁndings using the
Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Santa Rosa, California) versus the Taxus
Liberte paclitaxel-eluting stent (PES) (Boston Scientiﬁc, Natick, Massachusetts) in an all-comer
Chinese population.
Background Concerns regarding restenosis risk led to new-generation drug-eluting stents (DES) de-
signed for use in patients with complex clinical or lesion characteristics. In-stent late lumen loss
(LLL) is a measure of restenosis risk.
Methods Patients with an indication for treatment with a DES were randomized in a 1:1 ratio to
placement of at least 1 R-ZES or PES with minimal exclusions. The primary endpoint was angio-
graphic in-stent LLL at 9 months post-procedure. Clinical endpoints at 12 months are compared be-
tween the 2 stents.
Results A total of 198 patients received a R-ZES, and 202 patients received a PES. Most patients
were male; 25.8% and 29.2% of R-ZES and PES patients, respectively, had diabetes. Over 70% of le-
sions in both cohorts were American College of Cardiology/American Heart Association lesion classi-
ﬁcation Type B2 and C (B2/C). In-stent LLL was 0.16  0.38 mm for R-ZES and 0.33  0.52 mm for
PES at 9 months (p  0.001; 95% conﬁdence interval [CI]: 0.26 to 0.08). The rates of clinically
driven target lesion revascularization were 1.5% for R-ZES and 7.0% for PES (p  0.011). The rate of
target lesion failure was 5.6% for R-ZES and 11% for PES (p  0.068).
Conclusions In an all-comers Chinese population, 9-month in-stent LLL was signiﬁcantly less with
R-ZES compared with PES, which was reﬂected in lower revascularization rates at 12 months for the
R-ZES patients. Results are consistent with previous clinical trials of the R-ZES in all-comer popula-
tions. (Resolute Zotarolimus-Eluting Stent Versus the Taxus Liberte Paclitaxel-Eluting Stent for Percu-
taneous Coronary Intervention in China [R-China RCT]; NCT01334268). (J Am Coll Cardiol Intv 2013;
6:664–70) © 2013 by the American College of Cardiology Foundation
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665The use of quantitative angiographic endpoints to better
assess vascular response following stenting provides valuable
data regarding the biological effects of different drug-eluting
stents (DES). Late lumen loss (LLL) is an angiographic
measure of neointimal hyperplasia, the pathological target
of DES (1), and is considered a reasonable measure of
clinical restenosis risk (2). Earlier studies that used LLL as
a primary endpoint were done in simpler populations (3),
but angiographic data for new-generation DES in all-
comer populations are minimal. The RESOLUTE All-Comers
(A Randomized Comparison of a Zotarolimus-Eluting Stent
With an Everolimus-Eluting Stent for Percutaneous Cor-
onary Intervention) trial (R-AC) included angiographic
follow-up in only 20% of the patients, and a second similar
randomized controlled trial did not include any angio-
graphic follow-up (4,5).
We report here the first results of a randomized clinical
trial comparing the Resolute zotarolimus-eluting stent (R-
ZES) (Medtronic, Santa Rosa, California) with the Taxus
Liberte paclitaxel-eluting stent (PES) (Boston Scientific, Natick,
Massachusetts) in an all-comer Chinese population. The primary
endpoint is in-stent LLL at 9 months. This study, the first
randomized clinical trial of R-ZES conducted in China, was
designed to confirm the consistency of R-ZES outcomes in
real-world Chinese patients with coronary artery disease.
Methods
Study design and patient population. The RESOLUTE China
andomized Controlled Trial (R-China RCT) is a prospec-
ive, 2-arm, open-label study, designed to assess the non-
nferiority of the R-ZES compared with the PES. Patients
ere enrolled in the trial at 16 sites from September 2011 to
ovember 2011.
Ethics committees provided written approval for the
rotocol, and all patients gave written informed consent.
he study was conducted in accordance with the Declara-
ion of Helsinki and all local regulatory requirements.
Eligible patients were acceptable candidates for treatment
ith a DES with at least 1 R-ZES or PES. Patients were
xcluded if they were participating in an ongoing study or
ad planned surgery within 6 months of percutaneous
oronary intervention. No limitations were placed on the
umber of vessels and lesions to be treated.
Patients were randomized in a 1:1 ratio to stenting with
R-ZES or a PES using an interactive voice response
ystem. The randomization was stratified by site. If more
han 1 lesion was to be treated in a patient, all lesions were
lanned to be treated with the same assigned study stent
ype. The study management team, but not any of the study
nvestigators, who participated in the study, was blinded to
he assigned study stent. Dual antiplatelet therapy was to be
dministered according to hospital routine practice. The
re-procedural or periprocedural regimen was aspirin 100 mg and clopidogrel 75 mg for 3 days, or a loading dose of
spirin 300 to 600 mg and clopidogrel 300 to 600 mg. The
ost-procedural regimen was aspirin 100 mg daily (indefi-
itely) and 75 mg clopidogrel for at least 6 months.
Clinical follow-up was completed for 30 days, 6 and 9
onths, and 1 year and is scheduled annually through 5
ears. The angiographic follow-up was scheduled at 9
onths post-procedure for all patients.
Endpoints and deﬁnitions. The primary endpoint was an-
iographic in-stent LLL at 9 months post-procedure, de-
ned as the difference between the post-procedure minimal
umen diameter (MLD) and the follow-up MLD. Second-
ry angiographic endpoints included in-segment LLL, in-
tent and in-segment percent diameter stenosis (%DS),
n-stent and in-segment MLD, and in-stent and in-
egment binary restenosis rate.
inary restenosis was defined as
DS of 50%.
Device, lesion, and procedure
uccess have been previously de-
ned (4). Clinical endpoint def-
nitions were consistent with the
rior RESOLUTE trials and in-
luded death, cardiac death, tar-
et vessel myocardial infarction
TVMI), cardiac death and
VMI, clinically driven target
esion revascularization (TLR),
linically driven target vessel re-
ascularization (TVR), target
essel failure (TVF), target le-
ion failure (TLF), major ad-
erse cardiac events, and stent
hrombosis. Deaths were classi-
ed as cardiac death unless a
oncardiac cause could be posi-
ively identified. Stent thrombo-
is was adjudicated according to
he Academic Research Consor-
ium definition (6).
Safety reporting. The trial was 100% monitored. A blinded
angiographic core laboratory (Cardiovascular Research
Foundation, New York, New York) reviewed all baseline,
procedural, and 9-month follow-up assessments. An inde-
pendent, blinded clinical events committee adjudicated all
outcomes according to pre-specified definitions. An inde-
pendent data safety monitoring board reviewed outcomes on
a regular basis and could recommend study termination.
The Cardiovascular Research Foundation coordinated the
clinical events committee and data safety monitoring board.
Statistical analysis. This trial was powered to test whether
-ZES is noninferior to PES in the primary endpoint of
n-stent LLL in the R-ZES group, with a noninferiority
Abbreviations
and Acronyms
%DS  percent diameter
stenosis
CI  confidence interval
DES  drug-eluting stent(s)
LLL  late lumen loss
MI  myocardial infarction
MLD  minimal lumen
diameter
PES  paclitaxel-eluting
stent(s)
R-ZES  Resolute
zotarolimus-eluting stent(s)
TLF  target lesion failure
TLR  target lesion
revascularization
TVF  target vessel failure
TVMI  target vessel
myocardial infarction
TVR  target vessel
revascularizationargin of 0.16 mm. This margin was based on the
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666ENDEAVOR IV (Randomized Comparison of
Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Pa-
tients with Coronary Artery Disease) study comparing the
Endeavor zotarolimus-eluting stent to PES (7). R-ZES
would be considered noninferior to PES if the upper limit of
the 95% confidence interval (CI) of the difference of the
primary endpoint was 0.16 mm.
The primary and secondary endpoints were calculated
using an intention-to-treat population. Enrollment of 400
patients (assuming a 20% loss to follow-up rate) would
provide a power of 83% to demonstrate that R-ZES was
noninferior in the primary endpoint. Secondary outcomes
were compared between R-ZES and PES using the Fisher
exact test for categorical outcomes and a 2-sample t test for
continuous outcomes. Baseline characteristics were com-
pared between R-ZES and PES using the Fisher exact test
or Cochran-Mantel-Haenszel test for categorical variables
and a 2-sample t test for continuous outcomes. The Kaplan-
Meier method was used to analyze the time-sensitive nature
of TLF.
Figure 1. Patient Disposition
Baseline enrollment and follow-up rates at 30 days, 9 months, and 12 months
paclitaxel-eluting stent (PES). ITT  intention-to-treat.The 1-year TLF rate was compared between the 2
arms for a few pre-defined subgroups. The risk ratios and
95% CIs were calculated for those subgroups. The
outcomes for patients with and without diabetes were
also compared.
SAS software version 9.1 or later (SAS Institute; Cary,
North Carolina) was used for all statistical analyses. Values
p  0.05 were considered statistically significant.
Results
Patient disposition and characteristics. There were 400
atients randomized, 198 (264 lesions) to R-ZES and
02 (260 lesions) to PES. Nine-month angiographic
ollow-up is available for 148 R-ZES patients (74.7%)
nd 148 PES patients (73.3%). Clinical follow-up data at
2 months were available for 98.5% of R-ZES and 98%
f PES patients (Fig. 1). Dual antiplatelet therapy use at
2 months was high in both groups (96.9% for R-ZES
nd 95.5% for PES).
tients randomized to the Resolute zotarolimus-eluting stent (R-ZES) and thefor pa
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667Patients had a mean age of 60 years, most were male
(79%), and 28% had diabetes mellitus. Baseline character-
istics were similar between groups (Table 1). A mean of 1.7
stents per patient were used, and over 70% of lesions in both
groups were B2/C (Table 2). Device, lesion, and procedure
success were high for both stents (Table 2).
Primary and secondary angiographic endpoint. In-stent
LLL was 0.16 mm  0.38 mm in the R-ZES group and
0.33 mm 0.52 mm in the PES group at 9 months (Table 3,
Fig. 2). The primary endpoint was met (p  0.001 for both
noninferiority and superiority; 95% CI: 0.26 to 0.08).
The in-stent MLD of the PES group was significantly less
than that seen in the R-ZES group (2.26  0.68 mm vs.
2.44  0.56 mm, p  0.004). Additionally, in-stent and
in-segment %DS and binary restenosis were significantly
lower in the R-ZES group compared with the PES group
(Table 3).
Clinical endpoints. The 12-month rate of TLF was 5.6% for
he R-ZES group and 11% for the PES group (p  0.068)
Table 4, Fig. 3). The rates of clinically driven TLR (1.5%
s. 7%, p  0.011) and TVR (2% vs. 9%, p  0.003) were
ignificantly less in the R-ZES group compared with the
ES group (Table 4, Fig. 3). Cardiac death and TVMI were
imilar (p  0.809).
SUBGROUP ANALYSIS. The relative risk for TLF at 12
months for the overall population and selected subgroups
are shown in Figure 3. Baseline characteristics of the
-ZES and PES patients with and without diabetes were
Table 1. Baseline Characteristics
Characteristic
R-ZES
(n  198)
PES
(n  202)
p
Value
Age, yrs 59.7 9.9 59.6 10.6 0.986
Male 77.8% (154/198) 80.7% (163/202) 0.538
Current smoker 36.9% (73/198) 44.1% (89/202) 0.155
Diabetes mellitus 25.8% (51/198) 29.2% (59/202) 0.502
Hyperlipidemia 39.4% (78/198) 46.0% (93/202) 0.190
Hypertension 65.2% (129/198) 65.3% (132/202) 1.000
Previous MI 34.5% (67/194) 33.8% (67/198) 0.915
Previous PCI 14.6% (29/198) 20.8% (42/202) 0.117
Indication for revascularization 0.234
Stable angina 8.9% (17/190) 10.1% (19/189)
Unstable angina 63.7% (121/190) 71.4% (135/189)
Acute MI 26.8% (51/190) 18.0% (34/189)
Acute MI (within 72 h) 8.9% (17/190) 3.2% (6/189) 0.029
Complex* 55.1% (109/198) 48.5% (98/202) 0.195
Values aremean SD or% (n/N). *Complex patients were defined by the presence of at least 1 of
the following clinical or lesion characteristics: renal insufficiency (serum creatinine140mol/l),
left ventricular ejection fraction30%, acuteMI (72h),1 lesionper vessel,2 vessels stented,
lesions27 mm, bifurcations, bypass grafts, in-stent restenosis, unprotected left main coronary
artery, lesions with thrombus or total occlusion.
CABG coronary artery bypass graft; LVEF left ventricular ejection fraction;MImyocardial
infarction; PCI  percutaneous coronary intervention; PES  paclitaxel-eluting stent; R-ZES 
Resolute zotarolimus-eluting stent.imilar. There were no significant differences in 9-monthngiographic and any 12-month clinical endpoints between
atients with and without diabetes in either group.
iscussion
R-China RCT represents the largest reported population of
real-world R-ZES patients with angiographic follow-up in
the RESOLUTE global clinical program. The primary
endpoint of in-stent LLL was significantly lower following
percutaneous coronary intervention with the R-ZES com-
pared with the PES and met the noninferiority criteria of
the trial (0.16 0.38 mm vs. 0.33 0.52 mm, 2-sided 95%
I: 0.26 to 0.08, p  0.001).
The use of quantitative angiographic criteria of lumen
eterioration, namely, late loss, more closely reflects the
agnitude of the reactive intimal hyperplasia after stenting
8). A review examining the relationship between mean
LL and restenosis among different DES concluded that
LL is an excellent predictor of angiographic (binary
estenosis) and clinical (TVR) measures of restenosis with
o threshold phenomenon observed, suggesting that a lower
ean LLL correlates with a lower risk for revascularization
ver time (9).
An important feature of R-China RCT is that the
atients were enrolled within a 2-month period, suggesting
hat the majority of patients may have been concurrently
Table 2. Baseline Lesion, Device, and Procedure Characteristics
Characteristics
R-ZES
(n  198 Patients,
n  264 Lesions)
PES
(n  202 Patients,
n  260 Lesions) p Value
Calciﬁcation, moderate/
severe
7.6% (20/263) 10.4% (27/260) 0.264
B2/C lesions 70.8% (187/264) 70.0% (182/260) 0.849
Bifurcation 15.7% (31/198) 15.4% (31/202) 1.000
Small vessel (RVD 2.75 mm) 53.5% (106/198) 46.0% (93/202) 0.161
Long lesion (18 mm) 50.5% (100/198) 44.6% (90/202) 0.271
CTO 7.6%(15/198) 9.4% (19/202) 0.592
Vessel location per patient
LAD 53.5% (106/198) 55.0% (111/202) 0.841
LCX 30.3% (60/198) 30.2% (61/202) 1.000
RCA 38.4% (76/198) 33.2% (67/202) 0.298
Left main 1.0% (2/198) 1.5% (3/202) 1.000
Multivessel treatment 22.2% (44/198) 23.3% (47/202) 0.813
Stents per patient 1.7 0.9 1.7 1.0 0.926
Stents per lesion 1.2 0.5 1.3 0.5 0.724
Lesions treated per patient 1.3 0.6 1.3 0.6 0.909
Device success 97.0% (261/269) 96.9% (253/261) 1.000
Lesion success 100.0% (267/267) 100.0% (260/260)
Procedural success 96.9% (185/198) 96.0% (191/199) 0.787
Values are mean SD or % (n/N).
CTO  chronic total occlusion; LAD  left anterior descending coronary artery; LCX  left
circumflex;MLDminimal lumendiameter; RCA right coronary artery; RVD reference vesseldiameter; other abbreviations as in Table 1.
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668enrolled and were truly all-comers. Complex lesions (type
B2/C) occurred in 70% of the study population, and 55% of
the population met the criteria for complex, with 26%
Figure 2. Cumulative Distribution of In-Stent LLL
The cumulative distribution of in-stent late lumen loss (LLL) at 9 months
Table 3. Angiographic Outcomes
Lesion Characteristics
R-ZES
(n  198 Patients,
n  264 Lesions)
PES
(n  202 Patients)
(n  260 Lesions) p Value
Pre-procedure
RVD, mm 2.84 0.49 2.80 0.50 0.411
Lesion length, mm 19.09 10.18 18.16 10.18 0.309
MLD, mm 0.77 0.44 0.81 0.43 0.289
Diameter stenosis, % 72.81 14.34 71.11 14.09 0.173
Post-procedure
RVD, mm 2.88 0.48 2.86 0.51 0.564
In-stent
MLD, mm 2.61 0.44 2.57 0.46 0.308
Diameter stenosis, % 9.15 7.39 9.51 8.59 0.605
In-segment
MLD, mm 2.38 0.48 2.35 0.47 0.496
Diameter stenosis, % 17.60 8.78 17.67 7.84 0.924
9-month follow-up
RVD, mm 2.83 0.44 2.88 0.48 0.328
In-stent
Late lumen loss, mm 0.16 0.38 0.33 0.52  0.001
MLD, mm 2.44 0.56 2.26 0.68 0.004
Diameter stenosis, % 13.77 14.19 21.70 18.70 0.001
Binary restenosis* 2.5% (5/203) 10.7% (21/196)  0.001
In-segment
Late lumen loss, mm 0.15 0.41 0.24 0.49 0.062
MLD, mm 2.21 0.56 2.13 0.68 0.201
Diameter stenosis, % 21.99 14.41 26.52 18.01 0.006
Binary restenosis* 3.9% (8/205) 12.2% (24/196) 0.003
Values are mean SD or % (n/N).
Abbreviations as in Tables 1 and 2.t
post-stent implantation. Abbreviations as in Figure 1.diabetic patients, 37% current smokers, and 27% undergo-
ing revascularization following an acute myocardial infarc-
tion (MI), which is similar to the study populations enrolled
in the TWENTE (the Real-World Endeavor Resolute
Versus XIENCE V Drug-Eluting Stent Study in Twente)
trial (70% B2/C lesions, 22% diabetic patients, 28% with
acute MI) and the R-AC trial (67% complex, 24% diabetic
patients, 27% current smokers, and 34% with acute MI)
(4,5). The Chinese all-comer population is also comparable
with the RESOLUTE International (R-Int) trial popula-
tion (n  2,349); 30.4% had diabetes, 24.2% were current
smokers, and 29.7% had acute MI (10).
Compared with the LLL outcomes of R-China RCT,
the R-FIM (RESOLUTE First-in-Man) trial enrolled
fewer complex patients and reported 9-month in-stent LLL
of 0.22  0.27 mm (3).
The R-US (RESOLUTE US) trial also enrolled a less
complex population although 34% of patients had diabetes.
In the angiographic cohort, the mean in-stent LLL at 8
months was 0.30  0.54 mm (11). R-Japan (RESOLUTE
apan) reported a 9-month in-stent LLL of 0.12  0.22
m. The lower LLL in R-China RCT and R-Japan may be
ttributed to differences in procedural techniques utilized in
hese countries, which include use of adjunctive post-
ilation at a higher pressure after expansion.
Although our study is primarily an angiographic study,
e found consistent clinical outcomes compared with other
rials included in the RESOLUTE global clinical program.
comparison of the cumulative incidence of TLF at 12
onths for the 6 RESOLUTE trials illustrates this point
Fig. 4). Given the outcomes observed in R-China RCT,
Table 4. Clinical and Safety Outcomes at 12 Months
R-ZES
(n  197)
PES
(n  200) p Value
TLF 5.6 (11) 11.0 (22) 0.068
TVF 6.1 (12) 13.0 (26) 0.026
MACE 5.6 (11) 12.0 (24) 0.033
Cardiac death or TVMI 4.6 (9) 4.0 (8) 0.809
Death 1.0 (2) 1.0 (2) 1.000
Cardiac death 1.0 (2) 0.5 (1) 0.621
All MI 3.6 (7) 4.0 (8) 1.000
TVMI 3.6 (7) 3.5 (7) 1.000
All TLR 2.0 (4) 9.0 (18) 0.003
Clinically driven TLR 1.5 (3) 7.0 (14) 0.011
All TVR 2.5 (5) 11.0 (22) 0.001
Clinically driven TVR 2.0 (4) 9.0 (18) 0.003
ARC def/prob stent thrombosis 0.5 (1) 1.0 (2) 1.000
Late thrombosis (31–360 days) 0.0% (0) 0.5% (1) 1.000
Values are % (n).
ARC def/prob  Academic Research Consortium definite/probable; MACE  major adverse
cardiac events; TLF  target lesion failure; TLR  target lesion revascularization; TVF  target
vessel failure; TVMI target vessel myocardial infarction; other abbreviations as in Table 1.here does not appear to be an oculo-stenotic reflex affecting
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66912-month clinical outcomes for R-ZES as evidenced by the
fact that no additional events occurred between 9 and 12
months and might be attributed to the fact that improved
angiographic outcomes are less susceptible to the oculo-stenotic
reflex (12–15). However, the rates of TVF, clinically driven
TLR, and clinically driven TVR were significantly increased
in the PES arm of our trial at 12 months.
The rates of TLF for selected subgroups between patients
in each stent group showed results consistent with those
observed between the stents overall. The post hoc analysis
comparing R-ZES patients with and without diabetes
observed similar clinical and angiographic outcomes that are
0.0
Favors R-ZES 
0.1
Overall (n = 400)
Nondiabetics (n = 290)
Diabetics (n = 110)
ACS (n = 279)
Simple (n = 193)
Complex (n = 207)
Overlapping (n = 92)
Bifurcations (n = 62)
Multiple vessels (n = 91)
5.6
R-ZES
TLF rates (%)
4.8
7.8
7.2
4.5
6.4
4.3
3.2
6.8
11.0
PES
12.7
6.9
10.1
9.7
12.4
15.6
9.7
12.8
Figure 3. Risk for TLF at 12 Months for Selected Subgroups
ACS  acute coronary syndrome; CI  conﬁdence interval; TLF  target lesion
Figure 4. Cumulative Incidence of TLF for the RESOLUTE Global Clinical Tr
R-AC  RESOLUTE All-Comers; R-China  RESOLUTE China RCT; R-FIM  RESO
R-US  RESOLUTE US; TLF  target lesion failure.consistent with results reported from the pooled global
RESOLUTE clinical program. Patients with diabetes who
are not treated with insulin have comparable safety and
effectiveness to nondiabetic patients treated with a R-ZES
(16). These data are in contrast to earlier publications
suggesting that patients with diabetes have a higher risk for
restenosis than nondiabetic patients following bare-metal
stent or DES placement (17,18).
Study limitations. The sample size is small in terms of
linical comparisons; however, R-China RCT was primarily
esigned as an angiographic study and uses a sample size
imilar to other studies with angiographic primary end-
1.0 10.0
Favors PES 
0.051
p Value
0.018
0.851
0.404
0.173
0.142
0.075
0.305
0.345
0.51 (0.25-1.02)
Risk ratio (95% CI)
0.38 (0.16-0.88)
1.14 (0.30-4.32)
0.72 (0.33-1.56)
0.47 (0.15-1.44)
0.52 (0.21-1.27)
0.28 (0.06-1.27)
0.33 (0.04-3.03)
0.53 (0.14-2.01)
re. Other abbreviations as in Figure 1.
First-in-Man; R-Int  RESOLUTE International; R-Japan  RESOLUTE Japan;ials
LUTE
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670points (19). The small size of subgroups also limits the
ability to detect differences in clinical outcomes. Although a
higher rate of angiographic follow-up is desirable to fully
evaluate the angiographic outcomes, the statistical power of
the trial was preserved at 80% (20). Furthermore, the
present study enrolled a unique cohort of all-comer patients
with complex procedures, which differs from patients usu-
ally included in randomized trials and may limit the com-
pliance for angiographic restudy. The comparison is to a
first-generation DES currently less in use, rather than a
newer-generation DES. Longer-term follow-up will be
needed to confirm observed differences in revascularization.
Conclusions
This prospective, randomized, multicenter trial comparing
the R-ZES with the PES in an all-comer Chinese popula-
tion demonstrates a significantly lower in-stent LLL for the
R-ZES. The 12-month clinical outcomes are consistent with
other trials in the RESOLUTE global clinical program and are
significantly better than the comparator arm of the trial.
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